Communiqués Immatics N.V.

Actions

IMTX

NL0015285941

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 03/06/2024			Varia. 5j.	Varia. 1 janv.
12,13 ^USD	+9,97 %		+3,68 %	+15,19 %

15/05	IMMATICS N.V. : Mizuho Securities maintient sa recommandation à l'achat	ZM
14/05	Immatics réduit sa perte au premier trimestre. Le chiffre d'affaires augmente	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Immatics N : CONVENING NOTICE OF the ANNUAL GENERAL MEETING OF IMMATICS N.V - Form 6-K	03/06	PU
Immatics: Q1 Earnings Snapshot	14/05	AQ
Immatics N : Corporate Presentation May 2024	14/05	PU
Immatics Announces First Quarter 2024 Financial Results and Business Update	14/05	GL
Immatics N : Corporate Presentation March 2024	21/03	PU
Immatics Announces Full Year 2023 Financial Results and Corporate Update	21/03	GL
Immatics Announces Pricing of $175 Million Public Offering	18/01	GL
Immatics Announces Pricing of $175 Million Public Offering	18/01	AQ
Immatics Announces Proposed Public Offering	17/01	GL
Immatics Announces Proposed Public Offering	17/01	AQ
Immatics: Q3 Earnings Snapshot	14/11	AQ
Immatics Announces Third Quarter 2023 Financial Results and Business Update	14/11	GL
Immatics Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial	09/11	AQ
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial	08/11	GL
Immatics N : ACTengine® IMA203 Clinical Data Update at Society for Melanoma Research Congress, November 2023	08/11	PU
Immatics Receives FDA Regenerative Medicine Advanced Therapy Designation for ACTengine IMA203 TCR-T Monotherapy	25/10/23	AQ
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy	24/10/23	GL
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy	24/10/23	AQ
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors	13/09/23	AQ
MODERNA AND IMMATICS ANNOUNCE STRATEGIC MULTI-PLATFORM COLLABORATION TO DEVELOP INNOVATIVE ONCOLOGY THERAPEUTICS	12/09/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Immatics N.V.

Actions

IMTX

NL0015285941

Communiqués

Filtres